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Objectives: Evacuation of shed blood from around the heart and lungs is a critical
requirement for patients in early recovery after cardiac surgery. Incomplete evacuation
of shed blood can result in retained blood, which may require subsequent reinterven-
tions to facilitate recovery. The purpose of this studywas to determine the incidence of
retained blood requiring reintervention and examine the impact on outcomes.
Methods: We performed a cross-sectional, observational study of all adult pa-
tients undergoing cardiac surgery between 2006 and 2013. Subjects who required
an intervention to remove blood, blood clot, or bloodily fluid were attributed to the
retained blood group. These patients were compared with those not presenting
with any of the defined criteria for retained blood. Multivariate regression was
performed to account for confounders.
Results: Of 6909 adult patients who underwent cardiac surgery, 1316 (19%) pre-
sentedwith a retained blood-related condition. Retained bloodwas associatedwith
increased in-hospital mortality (odds ratio [OR], 4.041; 95% confidence interval
[CI], 2.589-6.351, P<.001) and a length of stay more than 13 days in the hospital
(OR, 3.853; 95% CI, 2.882-5.206; P<.001) and 5 days in the intensive care unit
(OR, 4.602; 95% CI, 3.449-6.183; P<.001). The OR for a time of ventilation
greater than 23 hours was 3.596 (95%CI, 2.690-4.851;P<.001) and for incidence
of renal replacement therapy was 4.449 (95% CI, 3.188-6.226; P<.001).
Conclusions: Postoperative retained blood is a common outcome and associated
with higher in-hospital mortality, longer intensive care unit and hospital stay, and
higher incidence of renal replacement therapy. Further research is needed to vali-
date these results and explore interventions to reduce these complications. (J
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rameters with respect to retained blood.Central Message
Postoperative retained blood is a common
complication after cardiac surgery and associ-
ated with compromised outcomes.Perspective
For patients recovering from cardiac surgery,
incomplete evacuation of shed blood can result
in retained blood around the heart and lungs
and impaired outcomes. However, this is a
potentially readily addressable problem,
because methods to actively clear drains of ob-
structions may be targeted through protocols
for quality-improvement initiatives in the ICU.See Editorial Commentary page 602.P
MPostoperative hemorrhage is one of the most common com-
plications in patients after heart surgery.1 Existing studies
identify a wide range of risk factors for bleeding, including
advanced age, nonelective surgery, low body surface area,
prolonged cardiopulmonary bypass time (>150 minutes),
complex procedures, number of bypass grafts (>5), and
preoperative use of antiplatelet agents.2-5 Bleeding is
associated with worse outcomes, including higher 30-day
mortality, higher incidence of stroke, intensive care unit
(ICU) stay more than 72 hours, mechanical ventilationQR code will take
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CABG ¼ coronary artery bypass grafting
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Mmore than 24 hours, and significantly increased costs.5,6 The
exact cause of the higher mortality and complications
related to bleeding has not been elucidated completely. In
theory, bleeding, as measured by output of chest tubes,
should be adequately addressed in the ICU with blood
transfusions, treatment with factor concentrates, and fluid
resuscitation until the bleeding is treated and resolves or
is corrected surgically. Yet, numerous studies demonstrate
that outcomes are considerably worse in patients who are
transfused with blood, leading to speculation that the poor
outcomes could be related directly to the negative
biologic impact of transfusions and anemia.7-9 However,
several recent studies have shown that adverse clinical
results and mortality due to bleeding is independent of the
need for transfusions or that limiting transfusions has no
beneficial effect or may even be harmful.10,11 These
findings raise the possibility that there may be other
mechanisms that contribute to poor outcomes in patients
bleeding after heart surgery.6,12,13
One mechanism by which patients’ bleeding may have
worse outcomes could be related to incomplete evacuation
of shed blood from around the heart and lungs in the early
hours after heart surgery. There are potentially several
causes of incomplete evacuation of shed blood. Recent sur-
veys and a prospective observational study demonstrated
that chest tube clogging is more common than previously
appreciated, suggesting that inadequate blood evacuation
leading to retained blood from around the heart and lungs
also may be affecting outcomes in patients who bleed after
heart surgery.14,15 Furthermore, chest tubes might be
positioned inefficiently, may be removed too early, or
may become kinked or bent when needed for drainage. If
shed blood is incompletely evacuated, blood can be
retained around the heart and lungs, which could
adversely affect outcomes. To explore this hypothesis
further, the objective of this study was to determine the
incidence of interventions for retained blood in a large
cardiac surgery database and examine, using logistic
regression analysis, whether this is an independent
variable contributing to adverse clinical outcomes in
patients recovering after heart surgery.MATERIALS AND METHODS
This was a cross-sectional, observational study derived from our insti-
tutional clinical databases. With the written consent of the federal data pro-
tection officer and the hospital ethics commission (EA1/034/13), clinical596 The Journal of Thoracic and Cardiovascular Surgroutine data from all patients who underwent cardiac surgery between
2006 and 2013 were extracted from the 2 electronic patient data manage-
ment systems at our hospital (COPRA System, Sasbachwalden, Germany,
and SAP,Walldorf, Germany) into an anonymized study database. Because
of the study’s retrospective design, the ethics commission waived the need
for informed consent for this study. Cardiac surgery was defined as a docu-
mented procedure on valves or vessels in proximity to the heart or coronary
vessels. All patients received 30F chest tubes. Pleural tubes were placed
when the pleural spacewas opened. On rare occasions, Jackson-Pratt drains
were used. The average number of chest tubes per patient was 1.71. Anti-
coagulation after surgery is managed per institutional protocol. Six hours
after ICU admission, aspirin (100 mg) and low-dose heparin (250 IE/h)
are given when the patient is judged hemodynamically stable with no signs
of bleeding (<100 mL/h drainage output) and when laboratory results do
not suggest coagulation disturbance. To capture the most clinically signif-
icant patient population with the primary end point, retained blood was
defined as any intervention to remove blood, blood clot, or bloody fluid,
such as interventions for tamponade or pericardial effusion, hemothorax,
or pleural effusion during the index hospitalization. This included any re-
exploration for bleeding (which uniformly requires washout of retained
blood), any pericardial window or pericardiocentesis, or any placement
of a chest tube in the pleural space or thoracentesis. Excluded were reop-
erations after the index cardiac surgery procedure when bleeding and
washout were not managed. When one of these prerequisites was present,
the patient was attributed to the ‘‘retained blood’’ group and compared with
patients not presenting with any of the defined criteria. Primary end points
were in-hospital mortality and length of hospital stay. Time to extubation,
incidence of any renal replacement therapy (ie, hemofiltration or hemodi-
alysis), and postoperative transfusion of packed red blood cells were
defined as secondary end points. Institutional transfusion triggers follow
written, standard operating procedures whereby patients receive transfu-
sion at a trigger of 7 g/dL after revascularization. For those who are not
completely revascularized, we use a trigger of 8 g/dL. In case of massive
transfusion, we aim for a hemoglobin level of 7 to 9 g/dL. These policies
did not change during the 7-year study period.16
In addition to basic patient characteristics, type, priority, and duration of
surgery as markers of its complexity and preoperative risk (Age, Creati-
nine, and Ejection Fraction17), and postoperative Acute Physiology and
Chronic Health Evaluation II admission scorewere assessed to characterize
the study population and to identify possible confounders. Preexistingmed-
ical conditions were derived from International Classification of Diseases,
10th Revision–coded diagnoses available from the patient data manage-
ment systems or paper-based patient records. Hemostatic disorder was
defined as prothrombin time ratio less than 60%, partial thromboplastin
time greater than 45 seconds, or thrombocytes less than 100,000/mL.Statistical Analysis
Descriptive analyses and statistical testing were performed using the R
Project of Statistical Computing 3.0.1. When normal distribution was ruled
out using the Kolmogorov–Smirnov test, results were given as medians and
interquartile ranges, and otherwise as mean  standard deviation. Qualita-
tive observations were characterized by numbers with percentage. Statisti-
cal significance among groups was analyzed univariately by the exact
nonparametric Kruskal–Wallis test and (pairwise) with the exact Mann–
WhitneyU test. Exact chi-square tests were used for qualitative data. Sepa-
rate multivariate logistic regressions were performed for any of the defined
study end points, adjusted for possible preoperative and perioperative con-
founding factors with stepwise backward selection. Whenever the response
variable was continuous (eg, length of hospital stay), the median of the
study population served as cutoff point. Odds ratios (ORs) with 95% con-
fidence intervals (CIs) were determined and used for graphical presenta-
tion. In addition, continuous variables were analyzed using robust
regression with Huber function. All regression models are reported in
Tables E1 and E2. Logistic regression analyses were completed by aery c August 2016
TABLE 1. Basic patient characteristics
[ALL]
N ¼ 6909
No retained blood
N ¼ 5593
Retained blood
N ¼ 1316 P n
Basic data
Age, y 69.0 [61.0-75.0] 69.0 [61.0-74.0] 71.0 [64.0-77.0] <.001 6909
Sex: F 1964 (28.4%) 1524 (27.2%) 440 (33.4%) <.001 6909
BMI 26.9 [24.3-30.1] 27.0 [24.4-30.2] 26.3 [23.8-29.7] .001 5168
Preexisting medical conditions
Coronary heart disease 5383 (77.9%) 4418 (79.0%) 965 (73.3%) <.001 6909
Left heart failure (>NYHA II) 2069 (29.9%) 1487 (26.6%) 582 (44.2%) <.001 6909
COPD 1184 (17.1%) 879 (15.7%) 305 (23.2%) <.001 6909
Endocrine disease 6334 (91.7%) 5074 (90.7%) 1260 (95.7%) <.001 6909
Peripheral vascular disease 1333 (19.3%) 1006 (18.0%) 327 (24.8%) <.001 6909
Atrial fibrillation 2054 (29.7%) 1432 (25.6%) 622 (47.3%) <.001 6909
Chronic renal insufficiency 1684 (24.4%) 1234 (22.1%) 450 (34.2%) <.001 6909
Hematocrit preoperatively 41.0 [37.0-43.0] 41.0 [38.0-44.0] 39.0 [35.0-43.0] <.001 4382
Hemostatic disorder 754 (10.9%) 570 (10.2%) 184 (14.0%) <.001 6909
Antiaggregation .044 5072
Mono antiplatelet therapy 2309 (45.5%) 1950 (46.3%) 359 (41.7%)
Dual antiplatelet therapy 1097 (21.6%) 903 (21.4%) 194 (22.6%)
F, Female; BMI, body mass index; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease.
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Mgraphical method for verifying the assumed linear relationship between the
LOGITand the influencing continuous variables.18 Details on missing data
have been reported in Tables 1 and 2. No specific measures were
undertaken regarding regression analyses, such as imputation. All tests
should be understood as constituting explorative analysis; no adjustment
for multiple testing has been made.
RESULTS
During the 8-year study period from 2006 to 2013,
6909 adult patients underwent cardiac surgery and qual-
ified for study inclusion. By using the definition of re-
tained blood, 1316 patients (19%) had 1 or more
intervention to remove blood, blood clot, or bloody fluid
from around the heart and lungs. This included patients
who had interventions for pericardial effusion
(n ¼ 135, 1.95%), tamponade (n ¼ 34, 0.49%), thora-
centesis (n ¼ 588, 8.51%), or hemothorax (n ¼ 212,
3.07%), and 476 patients (6.9%) who were returned to
the operating room for bleeding and washout of hema-
toma. Patients in the retained blood group had an average
of 1.7 conditions that were part of the composite. The
median number of days to retained blood interventions
was 4 days postoperatively (0-11). The median time to
thoracentesis was postoperative day 10 (5-17).
Table 1 shows the baseline patient characteristics and
preexisting medical conditions. Patients in the retained
blood group were slightly older, and the percentage of fe-
male patients was higher than in the other group. Except
for coronary heart disease, all medical conditions that had
been assessed were more frequently found in the retained
blood group. Preoperative anticoagulation did not differ be-
tween groups.
As shown in Table 2, the distribution of surgical proce-
dures in both groups was significantly different. WhereasThe Journal of Thoracic and Camore patients in the nonretained blood group underwent
coronary artery bypass grafting (CABG) surgery, CABG
and valve surgery were equally distributed in the retained
blood group. Also, combined procedures (ie, CABG and
valves) were performed more often in patients in the re-
tained blood group. Patients undergoing isolated CABG
had a retained blood rate of 15% (577/3954), patients un-
dergoing isolated valve CABG had a retained blood rate
of 24% (501/2093), and patients undergoing combined
CABG/valve surgery had a retained blood rate of 28%
(238/862). Likewise, priority of surgery affected the rate
of retained blood. Elective cases had a retained blood rate
of 22% (962/4361), urgent cases had a retained blood rate
of 64% (332/519), and emergency cases had a retained
blood rate of 55% (436/795). Because determinants that
are generally associated with compromised outcome (ie,
longer duration of surgery, emergency interventions, trans-
fusion) were more often found in the retained blood group,
we performed a subanalysis to investigate whether the
occurrence of retained blood was predictable from patients’
preoperative and perioperative characteristics. A Hosmer–
Lemeshow test with a P value less than .001 of the respec-
tive logistic regression model did not suggest any sufficient
calibration with those factors.
Hemodynamic instability and higher 24-hour chest tube
outputs were more often noted in the retained blood group.
In particular, patients in that group had lower mean arterial
pressure (69.6 [64.7-76.7] mm Hg vs 72.1 [66.2-78.3] mm
Hg, P < .001) and more often required norepinephrine
(72.3% vs 52.5%, P< .001) and epinephrine (42.4% vs
17.7%, P<.001) during the first 24 hours after surgery.
Parameters on patient outcome are shown in Table 3. In-
hospital mortality was significantly higher in patients in therdiovascular Surgery c Volume 152, Number 2 597
TABLE 2. Surgery-related data and presence of factors of the retained blood definition
[ALL]
N ¼ 6909
No retained blood
N ¼ 5593
Retained blood
N ¼ 1316 P n
Surgery
Type of surgery <.001 6909
CABG 3954 (57.2%) 3377 (60.4%) 577 (43.8%)
Valves 2093 (30.3%) 1592 (28.5%) 501 (38.1%)
Both 862 (12.5%) 624 (11.2%) 238 (18.1%)
Duration of surgery, min 195 [160-240] 195 [160-235] 200 [160-255] <.001 5706
Priority of surgery <.001 5675
Elective 4361 (76.8%) 3606 (79.0%) 755 (68.1%)
Urgent 519 (9.15%) 394 (8.63%) 125 (11.3%)
Emergency 795 (14.0%) 566 (12.4%) 229 (20.6%)
pRBC transfusion (pat.%) 1829 (29.6%) 1320 (26.2%) 509 (44.5%) <.001
pRBC transfusion, units 1.95 (1.05) 1.88 (0.97) 2.16 (1.23) <.001 6181
ACEF score 1.28 [1.13-1.60] 1.27 [1.12-1.54] 1.42 [1.22-1.95] <.001 6181
APACHE II 18.0 [14.0-24.0] 18.0 [14.0-23.0] 21.0 [16.0-27.0] <.001 4915
Retained blood-related factors 5763
Pericardial effusion 135 (1.95%) 0 (0.00%) 135 (10.3%) 6909
Hemothorax 212 (3.07%) 0 (0.00%) 212 (16.1%) 6909
Tamponade 34 (0.49%) 0 (0.00%) 34 (2.58%) 6909
Thoracentesis 588 (8.51%) 0 (0.00%) 588 (44.7%) 6909
CABG, Coronary artery bypass grafting; pRBC, packed red blood cells; ACEF, Age, Creatinine, and Ejection Fraction; APACHE, Acute Physiology and Chronic Health
Evaluation.
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Mretained blood group (19.7% vs 3.9%, P< .001). Also,
length of hospital stay (days) (25 [15-47] vs 12 [9-17],
P < .001) and ICU stay (days) (14 [7-30] vs 5 [3-7],
P<.001) were significantly increased. The time of ventila-
tion was longer (80 [26-308] vs 20 [9-40] hours, respec-
tively, P < .001). Any postoperative renal replacement
therapy (42.1% vs 10.1%, P< .001) and transfusion of
packed red blood cells (54.1% vs 10.0%, P<.001) were
more often required.
Patients in the retained blood group presented a high
number of conditions preoperatively and perioperatively
that may have had a negative impact on patient outcome.
In multivariate regression analyses, retained blood was
associated with an OR of 4.041 (95% CI, 2.589-6.351;
P<.001) for in-hospital mortality. A length of stay more
than 13 days in hospital (OR, 3.853; 95% CI, 2.882-
5.206, P< .001) or 5 days in the ICU (OR, 4.602; 95%
CI, 3.449-6.183; P< .001) was associated with a 5-fold
risk in patients in the retained blood group. Time ofTABLE 3. Patient outcomes
[ALL]
N ¼ 6909
Mortality (in-hospital) 475 (6.88%)
LOS (hospital) [d] 13.0 [9.00-21.0]
LOS (ICU) [d] 5.00 [3.00-9.00]
Time of ventilation [h] 23.0 [10.0-54.0]
Incidence of hemodialysis 1117 (16.2%)
Postoperative transfusion (pRBC) 1273 (18.4%)
LOS, Length of stay; ICU, intensive care unit; pRBC, packed red blood cells.
598 The Journal of Thoracic and Cardiovascular Surgventilation more than 23 hours had an OR of 3.596 (95%
CI, 2.690-4.851; P<.001), and incidence of hemodialysis
had an OR of 4.449 (95% CI, 3.188-6.226; P<.001). Pa-
tients in the retained blood group had a 6-fold risk of
requiring packed red blood cell transfusion postoperatively
(OR, 6.261; 95% CI, 4.628-8.481; P<.001). A summary of
ORs is graphically presented in Figure 1. Additional multi-
variate analyses of the study’s continuous end points
yielded that retained blood was associated with a 10.6-
day increment of a patient’s hospital stay (95% CI, 9.505-
11.768; P< .001) and a 5.0-day increment of ICU stay
(95% CI, 4.477-5.494; P < .001). Time of ventilation
increased by 24.3 hours (95% CI, 21.208-27.470;
P<.001). A complete list of adjusted confounders and in-
dividual regression models is available in Table E1.
DISCUSSION
In our own earlier research, we found that bleeding, as
measured by the volume of chest tube output, wasNo retained blood
N ¼ 5784
Retained blood
N ¼ 1316 P
216 (3.86%) 259 (19.7%) <.001
12.0 [9.00-17.0] 25.0 [15.0-47.0] <.001
5.00 [3.00-7.00] 14.0 [7.00-30.0] <.001
20.0 [9.00-40.0] 80.0 [26.0-308] <.001
563 (10.1%) 554 (42.1%) <.001
561 (10.0%) 712 (54.1%) <.001
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FIGURE 1. Graphical presentation of ORs of selected outcome parame-
ters of retained blood patients versus control. Each ratio presents the result
of a separate logistic regression with differing explanatory variables as
determined by stepwise backwards selection. Whenever the response var-
iable was continuous (eg, length of hospital stay), the median of the study
population served as cutoff point. ICU, Intensive care unit; pRBC, packed
red blood cells.
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Massociated with higher 30-daymortality, higher incidence of
stroke, ICU stay more than 72 hours, mechanical ventilation
more than 24 hours, and significantly increased costs.6,19
Dixon and colleagues12 similarly showed that the volume
of chest tube drainage was significantly associated with
adverse outcomes, including duration of hospital and ICU
stay, duration of mechanical ventilation, and rates of pneu-
monia, septicemia, hemofiltration, tracheostomy, reintuba-
tion, and readmission to the ICU after ward discharge.12
They concluded that the extent of chest tube drainage had
a dose-dependent relationship with the extent of decrease
in cardiac index and impairment in respiratory function in
the ICU.12 Why patients who bleed have far worse out-
comes is still a subject of debate.
One critical and perhaps overlooked aspect of the man-
agement of a bleeding patient is the absolute requirement
to evacuate the shed blood from around the heart and lungs
in the early hours of recovery in the ICU. We and others hy-
pothesized that an additional mechanism by which bleeding
patients may have poor outcomes could be related to inad-
equate chest tube drainage leading to retained blood.12
Because of the volumetrically confined mediastinal, peri-
cardial, and pleural spaces that contain the heart and lungs,
any bleeding must be promptly externalized with drainage
tubes to avoid internal bleeding that is not evacuated or
recognized. Chest tubes placed around the heart and lungsThe Journal of Thoracic and Cafitted to suction canisters are used in all patients to remove
this blood to keep the heart decompressed in the pericar-
dium and prevent compression of the lungs that can impair
respiratory function during early recovery. Clinicians caring
for patients after heart surgery are well aware that chest
tubes can clog, and when they do, adverse patient outcomes
can ensue.15 Prospective studies have shown that chest
tubes can become clogged with blood, impairing drainage
in up to 36% of patients.14 When clogging of a chest tube
occurs while a patient is still bleeding, the shed blood can
be retained around the heart and lungs. This raises the pos-
sibility that chest tube clogging leading to retained blood
may contribute to poor outcomes in patients recovering
from heart surgery. However, the incidence and conse-
quences of retained blood have never been studied. In addi-
tion, chest tubes can be placed in a way they are not in
continuity with a source of bleeding or become kinked or
bent, providing other mechanisms for incomplete evacua-
tion of shed blood during early recovery.
To explore this hypothesis further, we set out to deter-
mine the incidence and clinical consequences for patients
who require additional interventions for retained blood after
heart surgery. Our impression was that there was a contin-
uum of patients with retained blood from those who present
with enough retained blood to trigger a return to the oper-
ating room for reexploration and washout of clot to those
who present later with bloody effusions around the heart
and lungs. To minimize the potential to overestimate the
incidence in patients with clinically insignificant retained
blood, we focused on patients who required specific inter-
ventions to remove blood clot, blood, or bloody effusion
during a return to the operating room for reexploration for
bleeding with washout or during additional drainage proce-
dures for blood or bloody effusions, such as a pericardial
window, pericardiocentesis, pleural chest tube placement,
or thoracentesis. Using a definition whereby a specific
coded procedural intervention is required to remove re-
tained blood was thought to be more accurate and clinically
relevant than diagnosis codes because many patients can
have diagnostic codes for small effusions that do not turn
out to be clinically relevant.
In this study, 1316 of 6909 patients (19.0%) required a
retained blood-related intervention during early recovery
from heart surgery. Patients with retained blood were noted
to be significantly older and more likely female, and to have
lower body mass index. They were also more likely to have
left ventricular failure, chronic obstructive pulmonary dis-
ease, renal insufficiency, lower hematocrits, and hemostatic
disorders preoperatively. This suggests that high-risk
patients experience this outcome more commonly than
low-risk patients. However, we were able to rule out these
confounding factors in multivariate analyses, showing that
retained blood was an independent predictor for worse
outcome in all defined end points. Furthermore, we wererdiovascular Surgery c Volume 152, Number 2 599
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predictable by a patient’s preoperative and perioperative
characteristics. Likewise, we found that although patients
who bleed more are more likely to develop retained blood,
bleeding does not allow prediction of retained blood in
multivariate analysis.
Although many studies have focused on the need to reex-
plore patients to repair bleeding sources and wash out re-
tained blood, our study reveals an important number of
patients who have a more subacute form of retained blood,
that is, bloody effusions around the heart and lungs that
require interventions for drainage. Numerous studies have
shown that most effusions presenting in this time frame
early after surgery are bloody, exudative, and inflammatory,
providing a link in many cases with retained blood and the
subsequent development of effusions.20-24 Occasionally,
they can be from other causes, such as heart failure.
Likewise, early pericardial effusions are generally always
bloody, suggesting a similar cause related to retained
blood.25-27 The high incidence of effusions requiring
intervention after cardiac surgery suggests that targeting
chest tube management and retained blood for quality
improvement also may affect these outcomes.
Given the impact that retained blood has on clinical out-
comes, this raises the question if we are doing enough to
maximize blood evacuation for patients bleeding after car-
diac surgery. Although there can be numerous causes of
incomplete blood evacuation, one item that might
contribute in some cases is impaired chest tube patency.
Currently there are no published guidelines on best prac-
tices to maintain chest tube patency after cardiac surgery.
Chest tube manipulations, such as chest tube stripping or
milking, are commonly performed, but their safety and ef-
ficacy have been questioned.28 Day and colleagues29 re-
viewed the subject and found little evidence to support
the efficacy of chest tube manipulations to maintain
patency. They concluded that these practices may be harm-
ful because of negative pressures generated from this tech-
nique. Opening chest tubes and inserting items to break up a
clot are impractical for routine use and have safety con-
cerns.30,31 Recently available techniques to actively clear
chest tubes without breaking the sterile seal may allow
routine chest tube clearance that could reduce retained
blood.32,33 In a study by Sirch and colleagues,34 using the
same definition of retained blood, maintaining chest tube
patency reduced this complication by 43% in propensity-
matched patients.
Study Limitations
The present analysis has several limitations that are
important to acknowledge. This was a retrospective analysis
and therefore subject to investigator bias and errors in
manual extraction from the medical records. In addition,
not all the relevant factors, such as findings at reexploration600 The Journal of Thoracic and Cardiovascular Surgfor retained blood or the cytology of fluid removed by thor-
acentesis, were available for this analysis. The documenta-
tion of retained blood relied on specifically coded
interventions in themedical records and therefore is an accu-
rate measure of clinically significant retained blood. Given
the reliance on coded interventions for retained blood, and
not, for example, imaging studies, we may have underesti-
mated the real incidence of retained blood because some pa-
tients may have had retained blood that did not require an
intervention. To obtain the most accurate estimation of the
impact of retained blood on outcomes, subsequent studies
may be required to examine for more subtle forms of re-
tained blood that do not require an intervention, such as
those noted on imaging studies only. In addition, we did
not differentiate the results in regard to the causes of
bleeding (ie, examined whether the cause of bleeding was
surgical or caused by coagulopathy or if tamponadewas pre-
sent on reexploration).1,34,35 Further, it should be noted that
this studywas not designed to drawdefinitive conclusions on
the link of chest tube clogging with retained blood and did
not evaluate whether preventing chest tube clogging might
reduce this complication. However, the authors believe
that the high incidence of retained blood and the link with
adverse outcomes and mortality should draw attention to
the importance of adequate blood evacuation in the early
recovery after heart surgery.
CONCLUSIONS
Retained blood after cardiac surgery is common and
significantly associated with higher in-hospital mortality
and other postoperative complications. It is worse in
higher-risk patients who bleed more, but it cannot be
entirely predicted and can occur in any category of patient.
Incomplete evacuation of shed blood is a potentially readily
addressable problem that may be targeted through protocols
and quality-improvement initiatives in the ICU.
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TABLE E1. Logistic regression models of dichotomous and dichotomized outcome parameters. Stepwise backwards variable selection was
conducted in a regression model containing the following parameters: age, sex, BMI, type of surgery, priority of surgery, duration of surgery,
ACEF risk score, perioperative transfusion of pRBC, coronary heart disease, left heart failure (NYHA >II), COPD, peripheral vascular
disease, atrial fibrillation, chronic renal insufficiency, endocrine disease, hematocrit preoperative, hemostatic disorder, antiaggregation, and
Acute Physiology and Chronic Health Evaluation II on ICU admission
P OR 95% CI
Mortality
Retained blood <.001 4.041 2.589-6.351
Age (y) .014 1.036 1.008-1.066
BMI .100 1.037 0.993-1.082
Valves (CABG) .124 1.528 0.890-2.635
CABG þ valves (CABG) .047 1.784 1.005-3.157
Duration of surgery (min) <.001 1.006 1.003-1.008
ACEF .055 1.526 0.985-2.339
pRBC transfusion perioperative (unit) <.001 1.448 1.230-1.703
COPD .132 1.449 0.886-2.329
Peripheral vascular disease .007 1.997 1.198-3.271
Atrial fibrillation .004 1.969 1.235-3.150
Chronic renal insufficiency .022 0.555 0.331-0.911
Hemostatic disorder .034 1.707 1.032-2.785
APACHE II on ICU admission <.001 1.097 1.062-1.134
Length of stay (hospital)>23 d
Retained blood <.001 3.853 2.882-5.206
Valves (CABG) <.001 1.859 1.460-2.372
CABG þ valves (CABG) <.001 1.724 1.274-2.338
Urgent (elective) .118 0.761 0.540-1.069
Emergency (elective) .147 0.719 0.457-1.119
Duration of surgery (m) .035 1.002 1.000-1.003
ACEF .003 1.397 1.124-1.740
pRBC transfusion perioperative (unit) .037 1.134 1.008-1.277
COPD .020 1.361 1.051-1.765
Atrial fibrillation <.001 1.953 1.548-2.468
Chronic renal insufficiency .004 1.438 1.126-1.836
Endocrine disease .146 1.328 0.909-1.954
Hematocrit preoperatively .104 1.019 0.996-1.044
Hemostatic disorder .001 1.600 1.208-2.124
Antiaggregation mono .052 1.249 0.999-1.564
Antiaggregation dual .004 1.544 1.152-2.071
Length of stay (ICU)>5 d
Retained blood <.001 4.602 3.449-6.183
Age (y) .094 1.010 0.998-1.022
Urgent (elective) .728 1.067 0.738-1.534
Emergency (elective) .005 1.920 1.211-3.037
Duration of surgery (m) <.001 1.006 1.004-1.008
ACEF .001 1.526 1.184-1.969
pRBC transfusion perioperative (unit) .006 1.174 1.047-1.317
Left heart failure (>NYHA II) <.001 2.998 2.357-3.822
Atrial fibrillation <.001 2.162 1.700-2.750
Chronic renal insufficiency .043 1.303 1.007-1.684
Endocrine disease <.001 2.284 1.460-3.661
Hemostatic disorder .022 1.403 1.049-1.876
APACHE II on ICU admission .021 1.020 1.003-1.037
Time of ventilation>23 h
Retained blood <.001 3.596 2.690-4.851
Age (y) .007 1.015 1.004-1.027
BMI <.001 1.050 1.029-1.072
Urgent (elective) .080 1.363 0.964-1.933
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TABLE E1. Continued
P OR 95% CI
Emergency (elective) .095 1.445 0.938-2.231
Duration of surgery (m) <.001 1.007 1.006-1.009
ACEF .053 1.265 0.998-1.607
pRBC transfusion perioperative (unit) .118 0.916 0.820-1.022
Left heart failure (>NYHA II) <.001 2.473 1.948-3.148
COPD .038 1.326 1.017-1.733
Peripheral vascular disease .013 1.426 1.079-1.887
Atrial fibrillation .072 1.234 0.981-1.552
APACHE II on ICU admission <.001 1.035 1.019-1.052
Incidence of hemodialysis
Retained blood <.001 4.449 3.188-6.226
Age (y) .003 0.973 0.955-0.990
BMI .007 1.045 1.012-1.079
Valves (CABG) .048 1.470 1.002-2.154
CABG þ valves (CABG) .075 1.482 0.958-2.280
Duration of surgery (min) <.001 1.008 1.006-1.011
ACEF <.001 3.029 2.222-4.145
pRBC transfusion perioperative (unit) .007 1.223 1.057-1.413
Atrial fibrillation <.001 2.516 1.787-3.546
Chronic renal insufficiency <.001 2.672 1.900-3.760
Endocrine disease .003 4.589 1.832-13.415
Hematocrit preoperatively .013 0.959 0.927-0.991
Hemostatic disorder .070 1.423 0.967-2.078
APACHE II on ICU admission <.001 1.108 1.082-1.136
OR, Odds ratio; CI, confidence interval; BMI, body mass index; CABG, coronary artery bypass grafting; ACEF, Age, Creatinine, and Ejection Fraction; pRBC, packed red blood
cells; COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; NYHA, New York Heart Association.
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TABLE E2. Robust regression models of continuous outcome parameters. The same variables were considered as for logistic regression.
Estimate SE t P 95% CI
Length of stay (hospital)
Intercept 12.265 2.992 4.099 <.001 6.396-18.133
Age (y) 0.035 0.022 1.619 .106 0.078 to 0.007
Sex (female) 0.377 0.462 0.816 .415 0.529 to 1.283
BMI 0.066 0.041 1.628 .104 0.014 to 0.146
Valves (CABG) 2.609 0.761 3.430 .001 1.117-4.101
CABG þ valves (CABG) 2.058 0.607 3.393 .001 0.869-3.248
Urgent (elective) 0.983 0.674 1.458 .145 2.305 to 0.339
Emergency (elective) 1.056 0.855 1.235 .217 2.733 to 0.621
Duration of surgery (m) 0.011 0.003 3.425 .001 0.005-0.017
ACEF 1.045 0.48 2.178 .030 0.104-1.986
pRBC transfusion perioperative (unit) 0.989 0.248 3.990 <.001 0.503-1.475
Coronary heart disease 1.042 0.798 1.306 .192 0.523 to 2.607
Left heart failure (NYHA>II) 0.613 0.467 1.312 .190 0.303 to 1.528
COPD 1.215 0.522 2.328 .020 0.191-2.239
Peripheral vascular disease 0.745 0.543 1.371 .170 0.32 to 1.81
Atrial fibrillation 3.722 0.478 7.781 <.001 2.784-4.661
Chronic renal insufficiency 1.458 0.500 2.915 .004 0.477-2.439
Endocrine disease 1.397 0.741 1.885 .060 0.056 to 2.85
Hematocrit preoperatively 0.043 0.048 0.912 .362 0.05 to 0.137
Hemostatic disorder 1.603 0.564 2.841 .005 0.496-2.71
Antiaggregation 0.867 0.426 2.033 .042 0.031-1.703
APACHE II on ICU admission 0.063 0.031 2.070 .039 0.003-0.124
Retained blood 10.637 0.577 18.438 <.001 9.505-11.768
Length of stay (ICU)
Intercept 3.196 1.29 2.478 .013 0.667-5.726
Age (y) 0.002 0.009 0.255 .799 0.021 to 0.016
Sex (Female) 0.103 0.199 0.519 .604 0.287 to 0.494
BMI 0.016 0.018 0.911 .363 0.019 to 0.051
Valves (CABG) 0.230 0.330 0.698 .485 0.417 to 0.878
CABG þ valves (CABG) 0.384 0.264 1.455 .146 0.134 to 0.902
Urgent (elective) 0.455 0.294 1.549 .122 0.121 to 1.032
Emergency (elective) 1.254 0.376 3.336 .001 0.517-1.992
Duration of surgery (m) 0.012 0.001 8.786 <.001 0.009-0.015
ACEF 0.701 0.208 3.364 .001 0.292-1.11
pRBC transfusion perioperative (unit) 0.313 0.106 2.949 .003 0.105-0.52
Coronary heart disease 0.191 0.349 0.547 .584 0.493 to 0.874
Left heart failure (NYHA>II) 1.842 0.205 8.991 <.001 1.44-2.244
COPD 0.366 0.227 1.610 .107 0.08 to 0.812
Peripheral vascular disease 0.170 0.237 0.716 .474 0.295 to 0.634
Atrial fibrillation 1.735 0.210 8.256 <.001 1.323-2.148
Chronic renal insufficiency 0.543 0.216 2.512 .012 0.119-0.967
Endocrine disease 1.034 0.317 3.264 .001 0.413-1.655
Hematocrit preoperatively 0.010 0.021 0.498 .618 0.051 to 0.03
Hemostatic disorder 0.840 0.244 3.437 .001 0.361-1.319
Antiaggregation 0.066 0.185 0.356 .722 0.297 to 0.428
APACHE II on ICU admission 0.039 0.013 2.925 .003 0.013-0.065
Retained blood 4.985 0.259 19.236 <.001 4.477-5.494
Time of ventilation
Intercept 12.014 7.813 1.538 .124 27.336 to 3.308
Age (y) 0.023 0.057 0.41 .682 0.088 to 0.135
Sex (female) 1.386 1.206 1.149 .251 0.98 to 3.751
BMI 0.490 0.108 4.539 <.001 0.278-0.701
Valves (CABG) 3.125 2.010 1.555 .120 0.816 to 7.067
CABG þ valves (CABG) 3.543 1.625 2.18 .029 0.356-6.73
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TABLE E2. Continued
Estimate SE t P 95% CI
Urgent (elective) 2.825 1.796 1.573 .116 0.697 to 6.347
Emergency (elective) 3.974 2.288 1.737 .083 0.514 to 8.462
Duration of surgery (m) 0.091 0.009 10.528 <.001 0.074-0.108
ACEF 2.428 1.282 1.894 .058 0.085 to 4.942
pRBC transfusion perioperative (unit) 0.392 0.64 0.612 .541 1.647 to 0.864
Coronary heart disease 3.573 2.107 1.696 .090 0.559 to 7.705
Left heart failure (NYHA>II) 10.073 1.26 7.991 <.001 7.601-12.545
COPD 3.543 1.393 2.543 .011 0.81-6.275
Peripheral vascular disease 3.868 1.442 2.683 .007 1.041-6.696
Atrial fibrillation 7.806 1.284 6.082 <.001 5.289-10.323
Chronic renal insufficiency 3.599 1.315 2.736 .006 1.02-6.178
Endocrine disease 3.787 1.916 1.976 .048 0.029-7.545
Hematocrit preoperatively 0.028 0.126 0.225 .822 0.274 to 0.218
Hemostatic disorder 1.665 1.476 1.128 .259 4.559 to 1.229
Antiaggregation 1.411 1.119 1.261 .207 0.784 to 3.606
APACHE II on ICU admission 0.288 0.080 3.581 <.001 0.13-0.445
Retained blood 24.339 1.596 15.246 <.001 21.208-27.47
SE, Standard error; CI, confidence interval; BMI, body mass index; CABG, coronary artery bypass grafting; ACEF, Age, Creatinine, and Ejection Fraction; pRBC, packed red
blood cells; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive
care unit.
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